Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance

The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptoms responses, improved quality of life, and overall survival. Despite this, several unmet needs remain, including the absence of resis...

Full description

Bibliographic Details
Main Authors: Massimo Breccia, Francesca Palandri, Paola Guglielmelli, Giuseppe Alberto Palumbo, Alessandra Malato, Francesco Mendicino, Alessandra Ricco, Emanuela Sant’Antonio, Mario Tiribelli, Alessandra Iurlo
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Current Oncology
Subjects:
anemia
infection
intolerance
myelofibrosis
non-melanoma skin cancer
resistance
Online Access:https://www.mdpi.com/1718-7729/29/7/395

Internet

https://www.mdpi.com/1718-7729/29/7/395

Similar Items